Rakha EA - Search Results

1

Loss of the Nuclear Pool of Ubiquitin Ligase CHIP/STUB1 in Breast Cancer Unleashes the MZF1-Cathepsin Pro-oncogenic Program.

Luan H, Mohapatra B, Bielecki TA, Mushtaq I, Mirza S, Jennings TA, Clubb RJ, An W, Ahmed D, El-Ansari R, Storck MD, Mishra NK, Guda C, Sheinin YM, Meza JL, Raja S, Rakha EA, Band V, Band H. Luan H, et al. Among authors: rakha ea. Cancer Res. 2018 May 15;78(10):2524-2535. doi: 10.1158/0008-5472.CAN-16-2140. Epub 2018 Mar 6. Cancer Res. 2018. PMID: 29510992 Free PMC article.

2

High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses.

Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JF, Macmillan D, Blamey RW, Ellis IO. Abd El-Rehim DM, et al. Int J Cancer. 2005 Sep 1;116(3):340-50. doi: 10.1002/ijc.21004. Int J Cancer. 2005. PMID: 15818618

3

Prognostic markers in triple-negative breast cancer.

Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Rakha EA, et al. Cancer. 2007 Jan 1;109(1):25-32. doi: 10.1002/cncr.22381. Cancer. 2007. PMID: 17146782 Free article.

4

The p53 positive Bcl-2 negative phenotype is an independent marker of prognosis in breast cancer.

Rolland P, Spendlove I, Madjd Z, Rakha EA, Patel P, Ellis IO, Durrant L. Rolland P, et al. Among authors: rakha ea. Int J Cancer. 2007 Mar 15;120(6):1311-7. doi: 10.1002/ijc.22430. Int J Cancer. 2007. PMID: 17187363

5

Expression profiling technology: its contribution to our understanding of breast cancer.

Rakha EA, El-Sayed ME, Reis-Filho JS, Ellis IO. Rakha EA, et al. Histopathology. 2008 Jan;52(1):67-81. doi: 10.1111/j.1365-2559.2007.02894.x. Histopathology. 2008. PMID: 18171418 Review.

6

Patho-biological aspects of basal-like breast cancer.

Rakha EA, El-Sayed ME, Reis-Filho J, Ellis IO. Rakha EA, et al. Breast Cancer Res Treat. 2009 Feb;113(3):411-22. doi: 10.1007/s10549-008-9952-1. Epub 2008 Mar 9. Breast Cancer Res Treat. 2009. PMID: 18327637 Review.

7

Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance.

Habashy HO, Powe DG, Rakha EA, Ball G, Paish C, Gee J, Nicholson RI, Ellis IO. Habashy HO, et al. Among authors: rakha ea. Eur J Cancer. 2008 Jul;44(11):1541-51. doi: 10.1016/j.ejca.2008.04.020. Epub 2008 Jun 4. Eur J Cancer. 2008. PMID: 18538561

8

Triple-negative/basal-like breast cancer: review.

Rakha EA, Ellis IO. Rakha EA, et al. Pathology. 2009 Jan;41(1):40-7. doi: 10.1080/00313020802563510. Pathology. 2009. PMID: 19089739 Review.

9

Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen.

Habashy HO, Powe DG, Staka CM, Rakha EA, Ball G, Green AR, Aleskandarany M, Paish EC, Douglas Macmillan R, Nicholson RI, Ellis IO, Gee JM. Habashy HO, et al. Among authors: rakha ea. Breast Cancer Res Treat. 2010 Jan;119(2):283-93. doi: 10.1007/s10549-009-0345-x. Epub 2009 Feb 24. Breast Cancer Res Treat. 2010. PMID: 19238537

10

Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes.

Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG, El-Sayed ME, Benhasouna A, Brunet JS, Akslen LA, Evans AJ, Blamey R, Reis-Filho JS, Foulkes WD, Ellis IO. Rakha EA, et al. Clin Cancer Res. 2009 Apr 1;15(7):2302-10. doi: 10.1158/1078-0432.CCR-08-2132. Epub 2009 Mar 24. Clin Cancer Res. 2009. PMID: 19318481

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

522 results

Search Page

Filters